New combo could turn inoperable liver tumors into surgical candidates

NCT ID NCT07480382

Not yet recruiting Disease control Sponsor: Hong Wu Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new approach for people with liver cancer that cannot be removed by surgery. The treatment combines a procedure to grow the healthy part of the liver, chemotherapy directly into the liver, and two drugs (tislelizumab and lenvatinib) to shrink the tumor. The goal is to see if this combination can make the cancer removable and safe to operate on. About 30 adults aged 18-75 with right-sided liver cancer that hasn't spread will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INITIALLY UNRESECTABLE HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, 614000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••